ARTIDIS utilizes a nanotechnology platform to provide rapid cancer diagnosis and assess tumor aggressiveness by analyzing nanomechanical biomarkers in under three hours. This technology addresses the inefficiencies of traditional cancer diagnosis, which often leads to prolonged patient anxiety and unnecessary overtreatment.
Funding
$27M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnosis methods are slow and inefficient, often taking several days and causing significant anxiety for patients awaiting results. Existing tools also lack the accuracy needed to optimize treatment plans, leading to potential overtreatment or undertreatment.
Solution
ARTIDIS offers a nanotechnology-based platform for rapid cancer diagnosis and assessment of tumor aggressiveness, delivering results in under three hours. The ARTIDISNET platform analyzes nanomechanical biomarkers from tissue samples and integrates this data with patient clinical information to guide personalized therapy choices. By providing a data-driven diagnosis, ARTIDIS aims to reduce patient anxiety, improve treatment optimization, and enhance overall patient outcomes. The platform helps clinicians make more informed decisions, potentially preventing unnecessary overtreatment and improving the quality of life for cancer patients.
Target Audience
The primary target audience includes healthcare professionals, such as oncologists and pathologists, as well as hospitals and diagnostic laboratories involved in cancer diagnosis and treatment.
Features
- Nanotechnology-based analysis of nanomechanical biomarkers in tissue samples
- Rapid cancer diagnosis in under three hours
- ARTIDISNET platform integrating biomarker data with patient clinical information
- Personalized therapy guidance based on individual patient profiles
- Assessment of tumor aggressiveness to predict metastasis probability
- Data-driven diagnosis for improved treatment optimization